137 related articles for article (PubMed ID: 24839275)
1. Impact of cancer supportive care pathways compliance on emergency department visits and hospitalizations.
Kreys ED; Kim TY; Delgado A; Koeller JM
J Oncol Pract; 2014 May; 10(3):168-73. PubMed ID: 24839275
[TBL] [Abstract][Full Text] [Related]
2. Emergency room visits and hospital admission rates after curative chemotherapy for breast cancer.
Pittman NM; Hopman WM; Mates M
J Oncol Pract; 2015 Mar; 11(2):120-5. PubMed ID: 25585617
[TBL] [Abstract][Full Text] [Related]
3. Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-induced neutropenia.
Heaney ML; Toy EL; Vekeman F; Laliberté F; Dority BL; Perlman D; Barghout V; Duh MS
Cancer; 2009 Oct; 115(20):4839-48. PubMed ID: 19637341
[TBL] [Abstract][Full Text] [Related]
4. Annual patient and caregiver burden of oncology clinic visits for granulocyte-colony stimulating factor therapy in the US.
Stephens JM; Li X; Reiner M; Tzivelekis S
J Med Econ; 2016; 19(5):537-47. PubMed ID: 26745764
[TBL] [Abstract][Full Text] [Related]
5. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.
Wong SF; Chan HO
Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284
[TBL] [Abstract][Full Text] [Related]
6. Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study.
Tan H; Tomic K; Hurley D; Daniel G; Barron R; Malin J
Curr Med Res Opin; 2011 Jan; 27(1):79-86. PubMed ID: 21091127
[TBL] [Abstract][Full Text] [Related]
7. A retrospective study of patients' out-of-pocket costs for granulocyte colony-stimulating factors.
Tomic K; Long S; Li X; Fu AC; Yu TC; Barron R
J Oncol Pharm Pract; 2013 Dec; 19(4):328-37. PubMed ID: 23353712
[TBL] [Abstract][Full Text] [Related]
8. Comparative effectiveness of pegfilgrastim, filgrastim, and sargramostim prophylaxis for neutropenia-related hospitalization: two US retrospective claims analyses.
Henk HJ; Becker L; Tan H; Yu J; Kavati A; Naeim A; Deeter R; Barron R
J Med Econ; 2013; 16(1):160-8. PubMed ID: 23016568
[TBL] [Abstract][Full Text] [Related]
9. Prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer: a meta-analysis of randomized controlled trials.
Sung L; Nathan PC; Lange B; Beyene J; Buchanan GR
J Clin Oncol; 2004 Aug; 22(16):3350-6. PubMed ID: 15310780
[TBL] [Abstract][Full Text] [Related]
10. Variables associated with emergency department and/or unplanned hospital utilization for children with epilepsy.
Patel AD
Epilepsy Behav; 2014 Feb; 31():172-5. PubMed ID: 24434308
[TBL] [Abstract][Full Text] [Related]
11. Effect of primary prophylactic granulocyte-colony stimulating factor use on incidence of neutropenia hospitalizations for elderly early-stage breast cancer patients receiving chemotherapy.
Rajan SS; Lyman GH; Stearns SC; Carpenter WR
Med Care; 2011 Jul; 49(7):649-57. PubMed ID: 21478779
[TBL] [Abstract][Full Text] [Related]
12. Use of granulocyte colony-stimulating factor (G-CSF) in patients receiving myelosuppressive chemotherapy for the treatment of cancer. Provincial Systemic Treatment Disease Site Group.
Rusthoven J; Bramwell V; Stephenson B
Cancer Prev Control; 1998 Aug; 2(4):179-90. PubMed ID: 10093631
[TBL] [Abstract][Full Text] [Related]
13. Treatment-Related Complications of Systemic Therapy and Radiotherapy.
Jairam V; Lee V; Park HS; Thomas CR; Melnick ER; Gross CP; Presley CJ; Adelson KB; Yu JB
JAMA Oncol; 2019 Jul; 5(7):1028-1035. PubMed ID: 30946433
[TBL] [Abstract][Full Text] [Related]
14. Neutropenia-associated outcomes in adults with acute myeloid leukemia receiving cytarabine consolidation chemotherapy with or without granulocyte colony-stimulating factor.
Bradley AM; Deal AM; Buie LW; van Deventer H
Pharmacotherapy; 2012 Dec; 32(12):1070-7. PubMed ID: 23208834
[TBL] [Abstract][Full Text] [Related]
15. Documenting the benefits and cost savings of a large multistate cancer pathway program from a payer's perspective.
Kreys ED; Koeller JM
J Oncol Pract; 2013 Sep; 9(5):e241-7. PubMed ID: 23943896
[TBL] [Abstract][Full Text] [Related]
16. Discrete choice experiment to estimate breast cancer patients' preferences and willingness to pay for prophylactic granulocyte colony-stimulating factors.
Johnson P; Bancroft T; Barron R; Legg J; Li X; Watson H; Naeim A; Watkins A; Marshall DA
Value Health; 2014 Jun; 17(4):380-9. PubMed ID: 24968998
[TBL] [Abstract][Full Text] [Related]
17. Economic implications of using pegfilgrastim rather than conventional G-CSF to prevent neutropenia during small-cell lung cancer chemotherapy.
Tan Sean P; Chouaid C; Hettler D; Baud M; Hejblum G; Tilleul P
Curr Med Res Opin; 2009 Jun; 25(6):1455-60. PubMed ID: 19419340
[TBL] [Abstract][Full Text] [Related]
18. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer.
Crawford J; Ozer H; Stoller R; Johnson D; Lyman G; Tabbara I; Kris M; Grous J; Picozzi V; Rausch G
N Engl J Med; 1991 Jul; 325(3):164-70. PubMed ID: 1711156
[TBL] [Abstract][Full Text] [Related]
19. Colony-stimulating factor use and impact on febrile neutropenia among patients with newly diagnosed breast, colorectal, or non-small cell lung cancer who were receiving chemotherapy.
McCune JS; Sullivan SD; Blough DK; Clarke L; McDermott C; Malin J; Ramsey S
Pharmacotherapy; 2012 Jan; 32(1):7-19. PubMed ID: 22392824
[TBL] [Abstract][Full Text] [Related]
20. Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy-induced myelosuppression in patients with small cell lung cancer: Pooled analysis of three randomized phase 2 trials.
Ferrarotto R; Anderson I; Medgyasszay B; García-Campelo MR; Edenfield W; Feinstein TM; Johnson JM; Kalmadi S; Lammers PE; Sanchez-Hernandez A; Pritchett Y; Morris SR; Malik RK; Csőszi T
Cancer Med; 2021 Sep; 10(17):5748-5756. PubMed ID: 34405547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
